USP10 and familial pancreatic carcinoma: To identify which patients with pancreatic cancer could benefit from SAH-mAH2-5 treatment, we selected and established four PDO models (PDAC-1, PDAC-2, PDAC-3, and PDAC-R) with various expression levels of USP10 and N1ICD, including one with chemoresistance to GEM (PDAC-R), for in vitro cultivation and in vivo orthotopic transplantation to establish PDOX models (Fig. 8a, b).